NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has partnered with Israel's Meir Medical Center to develop a microRNA-based test to identify non-small cell lung cancer (NSCLC) patients who would benefit from a specific class of immunotherapeutics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.